BCL2 and Thrombocytopenia: However, ABT-737, like navitoclax, has demonstrated hematologic toxicity in vivo, including thrombocytopenia and neutropenia, due to the on-target depletion of non-senescent cells that rely on BCL-2/XL signaling for survival.